Production (Stage)
GRI Bio, Inc.
GRI
$1.36
$0.064.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.42% | 12.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 56.14% | -8.26% | |||
| Operating Income | -56.14% | 8.26% | |||
| Income Before Tax | 47.55% | -173.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 47.55% | -173.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.55% | -173.53% | |||
| EBIT | -56.14% | 8.26% | |||
| EBITDA | -56.17% | 8.27% | |||
| EPS Basic | 26.25% | 31.16% | |||
| Normalized Basic EPS | -46.10% | 65.25% | |||
| EPS Diluted | 63.13% | -37.69% | |||
| Normalized Diluted EPS | -46.10% | 65.25% | |||
| Average Basic Shares Outstanding | 7.01% | 164.12% | |||
| Average Diluted Shares Outstanding | 7.01% | 164.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||